

Sheet 1 of 1

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. <b>P51160</b>	SERIAL NO. <b>09/912,483</b>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT <b>Erskine, et al.</b>	
		FILING DATE <b>July 25, 2001</b>	GROUP <b>1614</b>

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
MM	AA	3,133,061	05-1964	Kirchner, F. K.			
	AB	4,108,998	08-1978	Demerson, et al.			
	AC	5,426,224	06-1995	Lee, et al.			
	AD	6,063,801	05-2000	LaVoie, et al.			
	AE	6,174,678	01-2001	Menzei, et al.			
	AF	SN 09/912,610	07-2001	Erskine, et al.			
	AG	SN 10/199,933	07-2002	Erskine, et al.			
	AF	SN 60/391,700	26 June 2002	Axten, et al.			
MM	AG	SN 60/391,710	26 June 2002	Axten, et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation Yes   No
MM	BA	WO/0043383	17 Jan 2000	PCT			
	BB	WO/0078748	13 June 2000	PCT			
	BC	WO/0208224	25 July 2001	PCT			
	BD	WO/107432	17 July 2000	PCT			
	BE	WO/107433	17 July 2000	PCT			
	BF	WO/224684	19 Sept 2001	PCT			
	BG	WO/0250040	19 Dec 2001	PCT			
	BH	WO/0256882	22 Jan. 2002	PCT			
	BI	WO/02/096907	25 May 2001	PCT			
	BJ	WO/02/096907	25 May 2001	PCT			
	BK	PCT/EP02/05708	25 May 2001	PCT			RECEIVED
	BL	WO/03/010138	26 July 2001	PCT			JUN 17 2003
	BM	PCT/EP03/00824	29 Jan. 2002	PCT			
MM	BN	PCT/EP03/00823	29 Jan 2002	PCT			OFFICE OF PETITIONS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

MM	CA	Le Bras et al. "La Détermination de la Chimosensibilité de Plasmodium Falciparum" (1987) Annales de Pédiatrie, 34(5), 349-356.
MM	CB	Girault et al., "Antimalarial, Antitrypanosomal, and Antileishmanial Activities and Cytotoxicity of Bis (9-amino-6-chloro-2-methoxyacridines): Influence of the Linker" (2000) J. Med. Chem., 43(14), 2646-2654.

EXAMINER *James Ahern* DATE CONSIDERED *7/17/03*

.EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIC  
DEC 03 2001

JC2A

Sheet 1 of 2

Form PTO-1449  
 U.S. Department of Commerce  
 Patent and Trademark Office

ATTY. DOCKET NO.  
 P51113

SERIAL NO.  
 09/912,610

**INFORMATION DISCLOSURE STATEMENT  
 BY APPLICANT**

JUN 12 2003  
 (Use several sheets if necessary)

APPLICANT  
 Erskine, et al.

FILING DATE  
 July 25, 2001

GROUP  
 Unknown 1651

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**


		Document Number	Date	Country	Class	Subclass	Translation Yes   No
2	AA	WO 00/21952	20.04.00	PCT			
2	AB	WO 99/37635	29.07.99	PCT			
2	AC	WO 00/21948	20.04.00	PCT			RECEIVED
							JUN 17 2003
							OFFICE OF PETITIONS

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

AD	Couturier, et al., "Bacterial death by DNA gyrase poisoning", <i>Trends in Microbiology</i> , 6(7): 269-275 (1998).
AE	Y. Pommier, "Diversity of DNA topoisomerases I and inhibitors", <i>Biochimie</i> , 80: 255-270 (1998).
AF	Smith, et al., "Quinazoline Derivatives. II. Synthesis of 4-(4'-Diethylamino-1'-methylbutyl-amino)-6-methoxyquinazoline (SN 12,253)", <i>Journal of American Chemical Society</i> , 68: 1301-1303 (1946).
AG	R.B. Merrifield, "Solid Phase Peptide Synthesis. I. the Synthesis of a Tetrapeptide", <i>Journal of American Chemical Society</i> , 85: 2149-2154 (1963).
AH	Neil Osheroff, "Eukaryotic Topoisomerase II Characterization of Enzyme Turnover", <i>The Journal of Biological Chemistry</i> , 261(21): 9944-9950 (1985).
AI	Drlica, et al., "DNA Gyrase, Topoisomerase IV, and the 4-Quinolones", <i>Microbiology and Molecular Biology Reviews</i> , 61(3): 377-392 (1997).
AJ	Neil Osheroff, "Biochemical Basis for the Interactions of Type I and Type II Topoisomerases with DNA", <i>Pharmacology &amp; Therapeutics</i> , 41: 223-241 (1989).
AK	D'Incalci, et al., "DNA-topoisomerase inhibitors", <i>Current Opinions in Oncology</i> , 5: 1023-1028 (1993).
AL	Capranico, et al., "DNA sequence selectivity of topoisomerases and topoisomerase poisons", <i>Biochimica et Biophysica Acta</i> , 1400: 185-194 (1998).
AM	Wessel, et al., "Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the $\alpha$ Isoform", <i>Cancer Research</i> , 59: 3442-3450 (1999).
AN	Hiasa, et al., "Topoisomerase IV Can Support <i>oriC</i> DNA Replication <i>in Vitro</i> ", <i>The Journal of Biological Chemistry</i> , 269(23): 16371-16375 (1994).

*John O.*

*09 Apr 03*



Sheet 2 of 2

U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. P51113	SERIAL NO. 09/912,610
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Erskine, et al.	
		FILING DATE July 25, 2001	GROUP Unknown 1651

AO	Fortune, et al., "Merbarone Inhibits the Catalytic Activity of Human Topoisomerase II $\alpha$ by Blocking DNA Cleavage", <i>The Journal of Biological Chemistry</i> , 273(28): 17643-17650 (1998).
AP	Chini, et al., "Regioalternating Selectivity in the Metal Salt Catalyzed Animolysis of Styrene Oxide", <i>Journal of Organic Chemistry</i> , 56: 5939 - 5942 (1991).
AQ	Anthony Maxwell, "Protein gates in DNA topoisomerase II", <i>Nature Structural Biology</i> , 3(2): 109-112 (1996).
AR	Nishibata, et al., "Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation.", <i>Tetrahedron</i> , 47(43): 8985-8990 (1991).
AS	Olland, et al., "Catalysis of ATP Hydrolysis by Two NH <sub>2</sub> -terminal Fragments of Yeast DNA Topoisomerase II", <i>The Journal of Biological Chemistry</i> , 274(31): 21688 - 21694 (1999).
AT	Roca, et al., "Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp", <i>Proceedings of the National Academy of Sciences USA</i> , 91: 1781 - 1785 (1994).
AU	Stingl, et al., "Process for the preparation of 2-(S)-piperazinecarboxylic acid by continuous resolution via diastereomeric salt pairs", <i>Tetrahedron: Asymmetry</i> , 8(7): 979-982 (1997).
AV	Anthony Maxwell, "DNA gyrase as a drug target", <i>Trends in Microbiology</i> , 5(3): 102 - 109 (1997).
AW	Critchlow, et al., "DNA Cleavage Is Not Required for the Binding of Quinolone Drugs to the DNA Gyrase-DNA Complex", <i>Biochemistry</i> , 35: 7387 - 7393 (1996).
AX	Capranico, et al., "DNA topoisomerase II poisons and inhibitors", <i>Cancer Chemotherapy and Biological Response Modifiers Annual</i> 17, Elsevier Science, Chapter 6, pp. 114-131 (1997).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

N:\ERGI\APPS\P51110\1449.doc

RECEIVED

JUN 17 2003

OFFICE OF PETITIONS